Bioanalytical approaches, bioavailability assessment, and bioequivalence study for waiver drugs: In vivo and in vitro perspective

Clinical Research and Regulatory Affairs

Volumn 27, Issue 2, 2010, Pages 32-41

  Faiyazuddin, Md ^a,b   Ahmad, Sarfaraz ^a   Mustafa, Gulam ^a   Ahmad, Farhan J ^a   Shakeel, Faiyaz ^c  

^a HAMDARD UNIVERSITY   (India)

^b INTEGRAL UNIVERSITY   (India)

^c AL ARAB MEDICAL UNIVERSITY   (Libyan Arab Jamahiriya)

Author keywords

Balance incomplete block designs; Bioavailability; Bioequivalence; Cross over design; In vivo in vitro correlation; Waiver drugs

Indexed keywords

GENERIC DRUG; KETOCONAZOLE; NEW DRUG;

ACCURACY; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG RESEARCH; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; MAXIMUM PLASMA CONCENTRATION; METHODOLOGY; PATIENT MONITORING; PHARMACODYNAMICS; REPRODUCIBILITY; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED STATES;

EID: 77952562201     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.3109/10601331003698517     Document Type: Review

References (51)

1. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-General considerations. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); Rocksville, MD 20857. October 2000.
2. Westlake WJ. Biopharmaceutical statistics for drug development. In: Peace KE, editor. Bioavailability and bioequivalence of Pharmaceutical formulations. New York: Marcel Dekker; 1988. p 329.
3. Benet LZ, Kentoke SR. Bioavailability and bioequivalence: an update. In: Tipins HP, editor. Design and analysis of bioavailability and bioequivalence studies. New Age International Ltd., Publisher; New York, USA. 1995. p 25.
4. Glieter CH, Klotz U, Kuhlmann J, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Muller C, Holz-Slomczyk M. When are bioavailability studies required? A German proposal. J Clin Pharmacol 1998;38:904-911.
5. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products: Notes for guidance on the investigation of bioavailability and bioequivalence; Draft; 1998.
6. Ansel HC. Introduction to pharmaceutical dosage forms. Philadelphia, PA: Lea & Febiger; 1985. p 71.
7. Abdu HM. Effect of test parameters on dissolution rate, bioavailability and bioequivalence. Easten, PA: Mack Publishing Company; 1989. p 145-171.
8. Patterson SD. A review of the development of statistical design and analytical techniques for assessing in vivo bioequivalence: part one. Indian J Pharm Sci 2001;63:81-100.
9. Prouddfoot SG. The science of dosage form design. In: Aulton ME, editor. Factors influencing bioavailability. Educational Low Priced Books; Churchill Livingstone, Edinburgh. 1993. p 131.
10. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 5th Edition, McGraw-Hill Companies Inc; New York, USA, 2005. p 607-641.
11. Dighe SV and Adams WP. Bioavailability and bioequivalence of oral controlled release products: a regulatory perspective. In: Welling PG, Tse FLS and Dighe SV. (Eds). Pharmaceutical Bioequivalence, Marcel Dekker, New York: 1991. p 35-66.
12. Blum HH, Schug BS. The biopharmaceutics classification system (BCS): class III drugs better candidates for BA/BE waiver? Eur J Pharm Sci 1999;9:117-121.
13. CPMP/EWP/QWP/1401/98 Rev.
14. Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, USA; August 2000.
15. Shafiq S, Shakeel F, Talegaonkar S, Ahmed JA, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion. Eur J Pharm Biopharm 2007;66: 227-243.
16. Shafiq S, Shakeel F, Talegaonkar S, Ahmed FJ, Khar RK, Ali M. Design and development of oral oil in water ramipril nanoemulsion formulation: in vitro and in vivo assessment. J Biomed Nanotechnol 2007;3:28-44.
17. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment. J Drug Target 2008;16:733-740.
18. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnol 2008;6:E8.
19. Shakeel F, Faisal MS, Shafiq S. Comparative pharmacokinetic profile of aceclofenac from oral and transdermal application. J Bioavail Bioeq 2009;1:13-17.
20. Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Philadelphia, PA: Lea & Febiger; 1984. p 315.
21. Banker UV. Pharmaceutical dissolution testing. New York: Marcel Dekker Inc.; 1992. p 347.
22. Welling PG. Pharmaceutical bioequivalence. In: Welling Peter G, Tse, Fransis LS, Dighe Shrikant V, editors. New York: Marcel Dekker Inc.; 1991. p 223.
23. Shah VP, Mdha KK, Dighe S, McGilveray IJ, Skelley JP, Yacobi A, Layloff J, Vishwanathan CT, Cook CT, McDowell RD, Pittaman G, Spector S. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetics studies. J Pharm Sci 1992;81:309-312.
24. Roland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia, PA: Lea & Febiger; 1980. p 287.
25. Schuriman DJ. Generic drugs, bioequivalence and pharmacokinetics. In: Sharma KN, Sharma KK, Sen P, editors. Bioavailability studies: Indian requirements. New Delhi, India: University College of Medical Sciences; 1990. p 119.
26. Metzler CM. Statistical criteria. In: Welling PG, Tse, Fransis LS, Dighe SV, editors. Pharmaceutical bioequivalence. New York: Marcel Dekker Inc.; 1991. p 35-66
27. Midha KK, Rawson MJ, Hubbard JW. Bioequivalence: Switchability and scaling. Eur J Pharm Sci 1998; 6: 87-91.
28. Westlake WJ. Symmetrical confidence intervals for bioequivalence trials. Biometrics 1976;32:741-744.
29. Schuirmann DJ. A comparison of the two one sided tests procedure and the power approach for assessing equivalence of bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
30. Food and Drug Administration. Guidance on statistical procedures for bioequivalence studies using a standard twotreatment crossover design. Food and Drug Administration; 1992. US department of Health and Human services, FDA, Rockville, MD 20857.
31. McGilveray IJ, Midha KK, Skelly JP, Dighe S, Doluisio J, French I, Karim A, Burford R. Consensus report from the biointernational 89: issues in the evaluation of bioavailability. J Pharm Sci 1990;10:945-946.
32. Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, Dobrinska MR, Endrenyi L, Fairweather W, Gillespie W, Gonzalez MA, Hooper J, Jackson A, Lesko LJ, Midha KK, Noonan PK, Patnaik R, Williams RL. Evaluation of orally administered highly variable drugs and drugs formulations. Pharm Res 1996;13:1590-1593.
33. Midha KK, McKay G. Bioequivalence; its history, practice, and future. AAPS J 2009;11: 664-670.
34. Ludden TM, Allerheiligen SRB, Browne TR, Koup JR. Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady state phenytoin concentration. Ther Drug Monit 1991;13:120-125.
35. Ekbohm G, Melander H. The subject by formulation interaction as a criterion for interchangeability of drugs. Biometrics 1989;45:1249-1254.
36. Schall R, Luus HG. On population and individual bioequivalence. Stat Med 1993;12:1109-1124.
37. Schall R. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar. Biometrics 1995;51:615-626.
38. Liu JP, Chow SC. On the assessment of variability in bioavailability/ bioequivalence studies. Commun Stat Theor Met 1992;21:2591-2607.
39. Sheiner LB. Bioequivalence revisited. Stat Med 1992;11: 1777-11188
40. Guilbaud O. Exact inference about the within subject variance 2 × 2 cross over studies. J Am Stat Assoc 1993;88:939-946.
41. Endrenyi L. A method for the evaluation of individual bioequivalence. Int J Clin Pharmacol Therap 1994;32:497-508.
42. Anderson S, Hauck WW. Consideration of individual bioequivalence. Int J Pharmacokinet Biopharm 1990;18: 259-273.
43. Food and Drug Administration. Guidance for industry: In vivo bioequivalence studies based on population and individual bioequivalence approaches. Food and Drug Administration; 1997. Rockville, USA; August 2000.
44. Hauck WW, Chen ML, Hyslop T, Patnaik R, Schuirmann D, Williams R. Mean difference vs variability reduction: tradeoffs in aggregate measures for individual bioequivalence FDA individual bioequivalence working group. Int J Clin Pharmacol Therap 1996;34:535-541.
45. Mehra ML. The handbook of drug laws. Allahabad, India: The Ashoka Press; 1990. p 466.
46. Das-Gupta P. Generic drugs, bioequivalence and pharmacokinetics. In: Sharma KK, Sen P, editors. Bioavailability studies: Indian requirements. New Delhi, India: University College of Medical Sciences; 1990. p 77.
47. Chaudhari GN, Tipnis HP, Doshi BS, Kulkarni RD. Bioequivalence studies in humans of indomethacin capsules marketed in India. Eur J Clin Pharmacol 1984; 26: 261-264
48. Venn RF. Principles and practice of bioanalysis. London: Taylor & Francis; 1992. p 342.
49. Smyth MR. Chemical analysis in complex matrices. New York: Ellis Horwood Limited; 1992. p 11.
50. Kochweser J, Richens A, Marks V. Therapeutic drug monitoring. Edinburgh: Churchill Livingstone; 1981. p 75.
51. Smith RV, Stewart JT. Textbook of biopharmaceutic analysis. Philadelphia, PA: Lea & Febiger; 1991. p 3.